Skip to main content
SpringerLink
Log in

Allogeneic Transplantation for Hodgkin’s Lymphoma

  • Chapter
  • First Online:
Allogeneic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

  • 1429 Accesses

Abstract

There are only approximately 7,500 cases of Hodgkin’s lymphoma diagnosed in the United States annually. While there is a bimodal distribution in incidence, the majority of cases occur in young adults 15-30 years of age [1]. Initial therapy is highly successful with progression-free survival (PFS) rates at 10 years of 70-90% for early stage disease and 60-70% for advanced disease. For those relapsing after initial therapy, 30-50% are long-term survivors after an autologous stem cell transplant, making this one of the most curable adult malignancies. However, a small minority of these typically young and otherwise healthy patients will relapse even after an autologous stem cell transplantation (ASCT) and it is for these rare patients that allogeneic transplantation has been increasingly considered. Initially discarded in the early 1990s as being too toxic utilizing myeloablative conditioning, allogeneic transplantation for this disease is increasing again based on the availability of reduced intensity regimens and therapies that have decreased mortality due to regimen-related toxicities, graft versus host disease (GVHD), and opportunistic infections. Whether or not this will be an effective approach for multiply resistant patients remains to be determined, making this one of the most controversial areas in 2008 in allogeneic transplantation. This chapter outlines modern therapy for this group of lymphomas and the potential utility of allogeneic transplantation in select patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Freedman AS, Nadler LM (1998) Malignancies of lymphoid cells. In: Fauci AS (ed) Harrison’s principles of internal medicine, 14th edn. McGraw-Hill, New York, p 708

    Google Scholar 

  2. Densmore JJ, Williams ME (2006) Lymphoproliferative diseases. In: Williams ME, Kahn MJ (eds) American society of hematology self-assessment program. Blackwell Publishing, Washington, DC, pp 260-264

    Google Scholar 

  3. Straus D, Portlock C, Qin J, Myers J (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, Vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) varsus ABVD alone for stages I, II, and IIIA non-bulky Hodgkin Disease. Blood 104:3483-3489

    Article  PubMed  CAS  Google Scholar 

  4. leMaignan C, Desablens B, Delwail V, Dib M, Berthou C (2004) Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 103:58-66

    Article  CAS  Google Scholar 

  5. Engert A, Franklin J, Eich H, Brillant C, Sehlen S, Cartoni C (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 25:3495-3502

    Article  PubMed  CAS  Google Scholar 

  6. Santoro A, Bonadonna G, Valagussa P, Zucali R, Vivani S, Villani F (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37

    PubMed  CAS  Google Scholar 

  7. Duggan D, Petroni G, Johnson J, Glick J, Fisher R, Connors J (2003) Randomized comparison of ABVD and MOPP/ABV Hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607-614

    Article  PubMed  CAS  Google Scholar 

  8. Aisnberg AC (1999) Problems in Hodgkins disease management. Blood 93:761-779

    Google Scholar 

  9. Josting A, Franklin J, May M, Koch P, Beykirch M, Heinz J (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the german Hodgkin’s lymphoma study group. J Clin Oncol 20:221-230

    Article  PubMed  Google Scholar 

  10. Bonfonte V, Santoro A, Vivani S, Devizzi L, Balzarotti M, Soncini F (1997) Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 15:528-534

    Google Scholar 

  11. Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341:1051-1054

    Article  PubMed  CAS  Google Scholar 

  12. Josting A, Raemakers J, Diehl V, Engert A (2002) New concepts for relapsed Hodgkin’s disease. Ann Oncol 13:117-121

    Article  PubMed  Google Scholar 

  13. Reece D, Connors J, Spinelli J, Barnett M (1994) Intensive therapy with cyclophosphamide, carmustane, etoposide +/- cisplatin and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood 83:1193-1199

    PubMed  CAS  Google Scholar 

  14. Moskowitz C, Nimer S, Zelenetz A, Trippett T (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin’s disease: Analysis by intent-to-treat and development of a prognostic model. Blood 97:616-623

    Article  PubMed  CAS  Google Scholar 

  15. Horning S, Chao N, Negrin R, Hoppe R (1997) High-dose therapy and autologous hematopoeitic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indicies. Blood 89:801-813

    PubMed  CAS  Google Scholar 

  16. Stiff P, Unger J, Forman S, McCall A (2003) The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A southwest oncology group phase II trial. Biol Blood Marrow Transplant 9:529-539

    Article  PubMed  Google Scholar 

  17. Josting A, Rudolph C, Mapara M (2005) Cologne high dose sequential chemotherapy in relapsed and refractory Hodgkin’s and aggressive non-Hodgkin’s lymphoma - results of a multi-center phase-II study. Ann Oncol 16(1):116-123

    Article  PubMed  CAS  Google Scholar 

  18. Ahmed T, Lake D, Beer M (1997) Single and double auto-transplants for relapsing/refractory Hodgkin’s disease: Results of two consecutive trials. Bone Marrow Transplant 19:449-454

    Article  PubMed  CAS  Google Scholar 

  19. Brice P, Divine M, Simon D, Coiffier B (1999) Feasability of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable relapse from Hodgkin’s disease. Ann Oncol 10:1485-1488

    Article  PubMed  CAS  Google Scholar 

  20. Fung H, Stiff P, Schriber J, Toor A (2007) Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 13:594-600

    Article  PubMed  Google Scholar 

  21. Akpek G, Ambinder RF, Piantadosi S, Abrams R (2001) Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 19:4314-4321

    PubMed  CAS  Google Scholar 

  22. Pedersen-Bjergaard J, Anderson M, Christiansen D (2000) Therapy-related acute myelogenous leukemia and myelodysplasia after high-dose chemotherapy and stem cell transplantation. Blood 95:3273-3279

    PubMed  CAS  Google Scholar 

  23. Miller J, Arthur D, Litz C, Neglia J (1994) Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83:3780-3786

    PubMed  CAS  Google Scholar 

  24. Vose JM, Bierman PJ, Anderson JR et al (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80:2142-2148

    PubMed  CAS  Google Scholar 

  25. VandenBerghe E, Pearce R, Taghipour G, Fouilard L, Goldstone AH (1997) Role of second transplant in the management of poor-prognosis lymphomas: a report from the European blood and bone marrow registry. J Clin Oncol 15:1595-1600

    PubMed  CAS  Google Scholar 

  26. Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649

    PubMed  CAS  Google Scholar 

  27. Anderson JE, Litzow MR, Appelbaum FR, Schoch G (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year seattle experience. J Clin Oncol 11:2342-2350

    PubMed  CAS  Google Scholar 

  28. Milpied N, Fielding A, Pearce R, Ernst P (1996) Alogeneic bone marrow transplantation is not better than autologous transplantation for patients with relapsed Hodgkin’s disease. J Clin Oncol 14:1291-1296

    PubMed  CAS  Google Scholar 

  29. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 14:572-578

    PubMed  CAS  Google Scholar 

  30. Anderlini P, Acholonu S, Okoroji G-J, Andersson B (2004) Donor leukocyte infusions in relapsed Hodgkin’s lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD, and disease response. Bone Marrow Transplant 34:511-514

    Article  PubMed  CAS  Google Scholar 

  31. Anderlini P, Giralt S, Andersson B, Ueno N (2000) Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin’s disease. Bone Marrow Transplant 26:615-620

    Article  PubMed  CAS  Google Scholar 

  32. Lush R, Jones S, Haynes A (2001) Advanced-stage, chemorefractory lymphocyte-predominant Hodgkin’s disease: Long-term follow-up of allografting and monoclonal antobody therapy. Br J Haem 114:734-735

    CAS  Google Scholar 

  33. Cooney J, Stiff P, Toor A, Parthasarathy M (2003) BEAM allogeneic transplantation for patients with Hodgkin’s disease who relapse after autologous transplantation is safe and effective. Biol Blood Marrow Transplant 9:177-182

    Article  PubMed  Google Scholar 

  34. Anderlini P, Saliba R, Acholonu S, Okoroji G-J, Donato M (2005) Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35:943-951

    Article  PubMed  CAS  Google Scholar 

  35. Peggs K, Hunter A, Chopra R, Parker A (2005) Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365:1934-1941

    Article  PubMed  Google Scholar 

  36. Alvarez I, Sureda A, Caballero M, Urbano-Ispizua A (2005) Nonmyeloablative stem cell transplantation is an effective therapy for refaractory or relapsed Hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 12:172-183

    Article  Google Scholar 

  37. Baron F, Storb R, Storer BE et al (2006) Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 25:4150-4157

    Article  Google Scholar 

  38. Robinson S, Schmitz N, Taghipour G, Sureda A (2004) Reduced intensity allogeneic stem cell transplantation for hodgkin’s disease. Outcome depends primarily on disease status at the time of transplantation (abstract). Blood 104: Abstract 2322

    Google Scholar 

  39. Sureda A, Robinson S, Ruiz de Elvira C (2003) Non ablative allogeneic stem cell transplantation reduces transplant related mortality in comparison with conventional allogeneic transplantation in relapsed and refactory Hodgkin’s disease: results of the European group for blood and marrow transplantation. Blood 2003:692a

    Google Scholar 

  40. Carella A, Cavaliere M, Lerma E (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and Non-Hodgkin’s lymphoma. J Clin Oncol 18:3918-3924

    PubMed  CAS  Google Scholar 

  41. Hahn T, Benekli M, Wong C, Moysich K (2005) A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin’s disease. Bone Marrow Transplant 25:557-566

    Article  Google Scholar 

  42. Tey S, Butler J, Durrant S, Hill G, Morton J, Kennedy G (2005) Correspondence: a prognostic model for prolonged event-free survival after autologous or allogeneic blood or bone marrow transplantatin for relapsed and refractory Hodgkin’s disease. Bone Marrow Transplant 36:553-554

    Article  PubMed  CAS  Google Scholar 

  43. Hahn T, McCarthy P Jr (2005) Response to Tey et al. Bone Marrow Transplant 36:554

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, Bone Marrow Transplant Program, Loyola University Stritch School of Medicine, Maywood, IL, USA

    William Broderick & Patrick Stiff

Authors
  1. William Broderick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Stiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospitals Case Medical Center, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Broderick, W., Stiff, P. (2010). Allogeneic Transplantation for Hodgkin’s Lymphoma. In: Lazarus, H.M., Laughlin, M.J. (eds) Allogeneic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-478-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-478-0_6

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-33-6

  • Online ISBN: 978-1-59745-478-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation